))
Lars Rosendal: Leadership as the differentiating factor when drug development is uncertain
Manage episode 382347600 series 3526489
Content provided by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sam Parnell & Ivanna Rosendal, Sam Parnell, and Ivanna Rosendal or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Today we speak with Lars Rosendal, the VP of Global Clinical Operations at LEO Pharma. We speak about how clinical development is an innovation game - and how both governments and patients are willing to pay for innovation.
Patients in many major diseases are well served. That means we need to push the innovation to bring something to market that is either much safer, or has a higher degree of efficacy.
When it comes to bringing a drug through the entire clinical value chain, there is a lot of uncertainty as it is. When you are trying to aim for innovation, the uncertainty increases.
What this uncertainty does to a company depends on the company size. Being in a mid-sized pharmaceutical company means that there is some room for taking risks, but also a need to balance the uncertainty with the need to ensure continued operations.
We dive into what this means for trial design in different stages of clinical trials - and how some of these stages can be outsourced, whereas others should be best kept in house to build relationships with HCPs pre-drug launch.
We speak about leadership in the clinical area - and the benefits of understanding the entire clinical life cycle. Drug development is both an innovation game and a horse race. Leadership is what will allow your organization to run fast - but also dare to fail in pursuit of a deep purpose.
Lars recently re-organized his leadership team to structurally ensure cross-functional collaboration and drive a competitive edge. We speak about the ideas behind this restructuring, and also how it has addressed some of the most stubborn challenges of our industry.
Off-mic, Lars Rosendal and Ivanna Rosendal did try to figure out if there is a family relation - but there did not appear to be one.
Guest:
Lars Rosendal
https://www.linkedin.com/in/lars-rosendal-2520a16/
________
Reach out to Sam Parnell and Ivanna Rosendal
Join the conversation on our LinkedIn page
66 episodes
Share
